Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.682 EUR 1.79% Market Closed
Market Cap: 28.3m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

P/FCFE
Price to FCFE

-2.7
Current
-1
Median
23.3
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-2.7
=
Market Cap
28.3m EUR
/
FCFE
-10.5m EUR
All Countries
Close
Market Cap P/FCFE
BE
Celyad Oncology SA
XBRU:CYAD
28.3m EUR -2.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 262 029.8
US
Abbvie Inc
NYSE:ABBV
320.5B USD 12.8
US
Amgen Inc
NASDAQ:AMGN
140.8B USD 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD 11.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD -79.3
US
Epizyme Inc
F:EPE
94.1B EUR -420.7
AU
CSL Ltd
ASX:CSL
137B AUD 77.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.4B USD 23.8
US
Seagen Inc
F:SGT
39.3B EUR -57.8
NL
argenx SE
XBRU:ARGX
36.5B EUR -114.2
 
BE
Celyad Oncology SA
XBRU:CYAD
Average P/FCFE: 29.8
Negative Multiple: -2.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 262 029.8
US
Abbvie Inc
NYSE:ABBV
12.8
US
Amgen Inc
NASDAQ:AMGN
23.7
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -79.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -420.7
AU
CSL Ltd
ASX:CSL
77.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
23.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.8
NL
argenx SE
XBRU:ARGX
Negative Multiple: -114.2

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A